Approach to the Management of Hypertriglyceridemia
description
Transcript of Approach to the Management of Hypertriglyceridemia
![Page 1: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/1.jpg)
Approach to theManagement of
Hypertriglyceridemia
Timothy A. Denton, M.D.Attending Cardiologist
High Desert Heart InstituteVictorville, CA
![Page 2: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/2.jpg)
![Page 3: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/3.jpg)
![Page 4: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/4.jpg)
Outline
•Lipids / Triglyceride metabolism•Etiology of hypertriglyceridemia•Therapy of hypertriglyceridemia•Special considerations
![Page 5: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/5.jpg)
Can you identify these?
![Page 6: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/6.jpg)
VLDL
B100
CI CIICII CIII
E
IDL B100
E
LDL B100
Chylomicrons
B100
CICII
CIII
E
AI
AII
AIV
B48
Remnants
B48
E
HDL2
AI
AII
AI
AII
HDL3
HDL1
AI
AII
![Page 7: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/7.jpg)
VLDL
Chylomicrons
Remnants
HDL2IDL
LDL
HDL1
HDL3
50-90 A
90-120 A
120-180 A
180-280 A
250-350 A
300-800 A
800-5000 A
>300 A
![Page 8: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/8.jpg)
Egg McMuffin
Calories 290Calories from fat 110Total fat 12 gSaturated fat 4.5 gCholesterol 235 mgSodium 790 mgCarbohydrates 27gProtein 17g
http://www.mcdonalds.com/countries/usa/
![Page 9: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/9.jpg)
Chylomycron Production
Intestinal Brush Border
![Page 10: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/10.jpg)
Triglyceride Concentration over Time
Ng et al. Arterio Thromb Vasc Biol 1995;15:2157-2164
![Page 11: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/11.jpg)
C = 8 - 24
Fatty Acids
Lipids
HO
O
Triglycerides
O
O
O
O
O
O
Phospholipids
O
O
O
O
O
PGO
O
![Page 12: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/12.jpg)
HO
Cholesterol
O
Cholesterol Ester
Fatty Acid
OHC
O
+H O H
C
O
![Page 13: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/13.jpg)
Fatty Acids
• Number of carbons are multiples of 2 (from Acetyl-CoA)• Length of FA
Short chain = 2-6 carbonsMedium chain = 8-14 carbonsLong chain = 16 +
• Saturated FA contain no double bonds• Monounsaturated FA contain 1 double bond• Polyunsaturated FA (PUFA) contain 2 or more double bonds• Many, many other types of FA
![Page 14: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/14.jpg)
Fatty Acids
C
H
H
C
H
H
C
H
C
H
C
H
H
C
H
Hcis
trans C
H
H
C
H
H
C
H
C C
H
H
C
H
HH
C
H
H
C
H
H
C
HH
CH
H CH
H
C
Cis is GOOD
C
H
H
C
H
H
C
H
C C
H
H
C
H
HH
Trans is BAD
![Page 15: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/15.jpg)
PUFA (polyunsaturated fatty acid) Nomenclature
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Common name - -Linoleic acidSystematic name - all cis-9,12-octadecadienoic acidSystematic name - cis-9, cis-12-octadecadienoic acidChemist’s name - 18:2 (9Z, 12Z) (Z=cis, E=trans)Chemist’s name - 18:2 9,12 (assume cis, indicate trans)Nutritionist’s name #1 - 18:2 (n-6)Nutritionist’s name #2 - 18:2 -6
HO
O
18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
![Page 16: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/16.jpg)
REALLY, REALLY Essential Fatty Acids
HO
O
Linoleic acid (18:2, n-6)
HO
O
-Linolenic acid (18:3, n-3)
Corn oilCotton seed oilLinseed oil (flax)Rapeseed (canola) oilSoya oilWalnut oil, walnutsPeanutsBeefSpinach
Fish oilseicosadocosa
Sardines, Salmon,Mackerel, Cod,Halibut, Herring,Trout, Tuna,Haddock
![Page 17: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/17.jpg)
Lipid Metabolism
Gut
LIPOPROTEINLIPASE
Fatty acids
Chylomicronremnant
Liver
Chylomicron
VLDL
IDL
LDL
Whatyou
make
Whatyoueat
1,000 mg/day 300 mg/day
Bile
![Page 18: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/18.jpg)
Lipemia
![Page 19: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/19.jpg)
Apo B-48
Chylomicron Metabolism
Apo A-1
Apo C-II
Apo A-IV
Gut
Apo E
Apo C-III
LIPOPROTEINLIPASE
Fatty acidsApo A-1, A-IV
Apo C-II, C-III
Chylomicronremnant
= cholesterol
= triglyceride
= phospholipid
Liver
= cholesterol ester
![Page 20: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/20.jpg)
Fatty Acid Transport
Triglyceride-richlipoprotein
Lipoproteinlipase
ApoC-II
Fatty acids
Triglyceridesynthesis
lipase
Triglyceridestorage
Energy
FATTY ACID-ALBUMIN COMPLEXES
Liver
Adipose tissue
Muscle
Fattyacids
![Page 21: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/21.jpg)
LDL and IDL
![Page 22: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/22.jpg)
Metabolism of VLDLApo B-100
Apo E
NascentVLDL
Mature VLDL
VLDLRemnant
LDL
Liver LIPOPROTEINLIPASE
HDLCholesterol esters
Apo E
Apo EApo C-II,C-III
PhospholipidsFattyacidsHDL
Apo C-II, C-III
Apo C-III
Apo C-II
Fibr
ates
![Page 23: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/23.jpg)
Etiology• Genetic
Familial dysbetalipoproteinemiaFamilial combined hyperlipoproteinemiaFamilial hypertriglyceridemia (unknown)LPL deficiency / inhibitionApo C-II deficiency (LPL activator)Apo E defects / Apo E-2
• AcquiredDietAlcoholUremiaPregnancyDrug useHypothyroidism
![Page 24: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/24.jpg)
Type LP Chol TG Athero %I Chylo + ++++ - <1IIa LDL ++ + +++ 10IIb LDL+VLDL ++ ++ +++ 40III IDL ++ +++ +++ <1IV VLDL + ++ + 45V Chylo + VLDL + ++++ + 5
Fredrickson Classification
![Page 25: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/25.jpg)
LDL Cholesterol Goals and Cutpoints for Therapeutic LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)Lifestyle Changes (TLC)
and Drug Therapy in Different Risk Categoriesand Drug Therapy in Different Risk Categories
LDL Cholesterol Goals and Cutpoints for Therapeutic LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)Lifestyle Changes (TLC)
and Drug Therapy in Different Risk Categoriesand Drug Therapy in Different Risk Categories
190 190 (160–189: LDL-(160–189: LDL-
lowering drug optional)lowering drug optional)160160<160<1600–1 Risk Factor0–1 Risk Factor
10-year risk 10–20%: 10-year risk 10–20%: 130130
10-year risk <10%: 10-year risk <10%: 160 160
130130<130<1302+ Risk Factors 2+ Risk Factors
(10-year risk (10-year risk 20%)20%)
130 130 (100–129: drug (100–129: drug
optional)optional)100100<100<100
CHD or CHD Risk CHD or CHD Risk EquivalentsEquivalents
(10-year risk >20%)(10-year risk >20%)
LDL Level at Which LDL Level at Which to Considerto Consider
Drug Therapy Drug Therapy (mg/dL)(mg/dL)
LDL Level at Which to LDL Level at Which to Initiate Therapeutic Initiate Therapeutic Lifestyle Changes Lifestyle Changes
(TLC) (mg/dL)(TLC) (mg/dL)LDL GoalLDL Goal(mg/dL)(mg/dL)Risk CategoryRisk Category
![Page 26: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/26.jpg)
Approach to the treatment ofHypertriglyceridemia
• Elevated TG’s>200 mg/dl
• “Abdominal” TG’s>500-1000 mg/dl
![Page 27: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/27.jpg)
Therapy of Hypertriglyceridemia
• Underlying cause• Diet• Drugs• Plasmapheresis• Special considerations
![Page 28: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/28.jpg)
Underlying Cause
• EtOH• DM• Obesity• HIV drugs
![Page 29: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/29.jpg)
Underlying Cause
![Page 30: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/30.jpg)
Central Obesity Contributes to Insulin Resistance
Abdominal fat:high rate of FA turnoverhigh rate of lipolysis
![Page 31: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/31.jpg)
Classic Diabetic Lipid Pattern
• Low HDL• High LDL• High TG’s
![Page 32: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/32.jpg)
HIV Drugs
• HIV itself• Protease inhibitors• Unclear etiology• High TG’s (800-3000 mg/dl)• Low HDL (as low as 1 mg/dl)• High LDL (300-800 mg/dl)
![Page 33: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/33.jpg)
Diet
![Page 34: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/34.jpg)
Ornish D, et al. Lancet 1990;336:129
Lifestyle Heart Trial
Changes in Fat Intake
31.5
6.8
30.1 29.5
0
5
10
15
20
25
30
35
40
45
50
Baseline 1 year
Die
tary
Per
cen
t F
at
![Page 35: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/35.jpg)
Ornish D, et al. Lancet 1990;336:129
Lifestyle Heart Trial
Change in Serum Lipids(Intervention Group)
222
168
148
93
38 37
90110
0
50
100
150
200
250
Baseline 1 year
Die
tary
Per
cent
Fat
TCholLDLHDLTG
![Page 36: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/36.jpg)
Dietary Goals
• NOT total fat reduction
• Total fat 10-20%
![Page 37: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/37.jpg)
Partial Ileal Bypass
![Page 38: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/38.jpg)
POSCH --Program On Surgical Control of Hyperlipidemias
-37.7
4.3
19.8
-50
-40
-30
-20
-10
0
10
20
LDL HDL TG
Per
cent
Cha
nge
Arch Int Med 1998;158:1253
![Page 39: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/39.jpg)
Drugs
• Statins• Niacin• Fibrates• Fish oil
![Page 40: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/40.jpg)
Statins
Jones et al. Am J Cardiol2003;92:152
6
-30
-13
6.8
-45.8
-18.2
2.1
-51.1
-28.2
9.6
-55
-26.1
-60
-50
-40
-30
-20
-10
0
10
20
HDL LDL TG
Prava Simva Atorv Rosuva
![Page 41: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/41.jpg)
NiacinNicotinic acid
Niacin(Vit B3)
N
O
HO
N
O
NH2
Nicotinamide(no antilipemic activity)
![Page 42: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/42.jpg)
Niacin Forms
Generic Trade Dose TG effect LDL effect Niacin OTC 0.25-6g/day -35-55% -30%
Slo-Niacin (Polygel)
OTC 0.25-6g/day “ -30%
Niacin-inositol No-Flush Niacin
3-7 tabs/day (625 mg)
“ -19.1%
Long-acting Niacin
Niaspan 3-7 tabs/day (625 mg)
“ -19.1%
![Page 43: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/43.jpg)
Niacin Onset of Action
![Page 44: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/44.jpg)
Apo B PathwayApo B-100
Apo E
NascentVLDL
Mature VLDL
VLDLRemnant
LDL
Liver LIPOPROTEINLIPASE
HDLCholesterol esters
Apo E
Apo EApo C-II,C-III
PhospholipidsFattyacidsHDL
Apo C-II, C-III
Apo C-III
Apo C-II
Niacin
Niacin
![Page 45: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/45.jpg)
Fibrates
Drug Dosing Availability Clofibrate 600 bid YES Gemfibrozil 300 bid YES Fenofibrate 54, (107), 160 qd YES Bezafibrate 3x/day NO
![Page 46: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/46.jpg)
Effect of Fibrates on Lipid Levels
VA-HIT NEJM 1999;341:410
• Increased Lipoprotein lipase activity• Increased liver uptake of FA, decreased TG production• Increased LDL affinity for receptor• Lower exchange between LDL and VLDL• Increased HDL production• PPARs
![Page 47: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/47.jpg)
Effect of Fibrates on Lipid Levels
0
6
-31
-50
-40
-30
-20
-10
0
10
20
LDL HDL TG
Per
cent
Cha
nge
VA-HIT NEJM 1999;341:410
![Page 48: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/48.jpg)
Effect of FenoFibrate on Lipid Levels
-19
11
-28.9
-23
9.8
-23.5
-17
14.6
-35.9
-50
-40
-30
-20
-10
0
10
20
LDL HDL TG
Per
cent
Cha
nge
MeanTg<150Tg>150
![Page 49: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/49.jpg)
LDL Profile of FenofibrateLDL Profile of Fenofibrate LDL Profile of FenofibrateLDL Profile of Fenofibrate
-60%
-40%
-20%
0%
20%
40%
60%
Caslake; Arterioscler Thromb 1993:13;702-11
% C
hang
e
TC LDL-C LDL Receptor Uptake
Large Buoyant
LDL
Small Dense LDL
![Page 50: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/50.jpg)
BIPBezafibrate Infarction Prevention Study
Circulation 2000;102:21-27
Endpoint Bezafibrate(%)
Placebo(%)
P
Non-fatal MI 9.7 11.2 0.18
Fatal MI 1.2 1.1 0.87
SCD 2.8 2.8 0.98
UA 4.9 5.3 0.61
CABG 9.3 10.2 0.41
PTCA 5.9 5.7 0.84
All endpoints 33.7 36.3 0.14
Cardiac mortality 6.1 5.7 0.61
Noncardiac mortality 4.3 4.2 0.87
CVA 4.6 5.0 0.66
![Page 51: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/51.jpg)
Diabetes Atherosclerosis Intervention StudyDiabetes Atherosclerosis Intervention StudyDAISDAIS
Diabetes Atherosclerosis Intervention StudyDiabetes Atherosclerosis Intervention StudyDAISDAIS
1.1. DM II, DM II, with and without coronary interventionwith and without coronary intervention
2.2. Randomized, prospectiveRandomized, prospectivefenofibrate vs placebofenofibrate vs placebo
3.3. 418 randomized418 randomized4.4. Follow-up - 39.6 monthsFollow-up - 39.6 months5.5. End-pointsEnd-points
minimum lumen diameterminimum lumen diametermean segment diametermean segment diametermean % stenosismean % stenosis
![Page 52: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/52.jpg)
Diabetes Atherosclerosis Intervention StudyDiabetes Atherosclerosis Intervention StudyDAISDAIS
Diabetes Atherosclerosis Intervention StudyDiabetes Atherosclerosis Intervention StudyDAISDAIS
3.65
-0.1
0.08
2.11
-0.06 -0.06
-2.0
-1.0
0.0
1.0
2.0
3.0
4.0
%Stenosis MinDiam MeanDiam
PlaceboFenofibrate
P=0.02
P=0.03 P=0.17
![Page 53: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/53.jpg)
FenofibrateFenofibrate Adverse Events Adverse Events FenofibrateFenofibrate Adverse Events Adverse Events
Generally well toleratedGenerally well tolerated Most frequent discontinuation - rash (6% vs 2%)Most frequent discontinuation - rash (6% vs 2%) Other events: pruritis, constipation, diarrheaOther events: pruritis, constipation, diarrhea G.I. Upset 2% ( less than placebo)G.I. Upset 2% ( less than placebo) LFTs elevations 6.3% vs 2.1% for placeboLFTs elevations 6.3% vs 2.1% for placebo Increased warfarin levels (monitor INR)Increased warfarin levels (monitor INR)
![Page 54: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/54.jpg)
PPARs are theCENTER of the UNIVERSE
Peroxisome Proliferator Activated Receptor
PPARα -- FibratesPPARγ -- Thiazolidinediones
![Page 55: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/55.jpg)
PPARα Stimulation:
1. Reduces production of Apo CIII (inhibitor of lipolysis)
2. Activates Lipoprotein Lipase
3. Fall in TG levels
4. Switch from small dense to large “fluffy” LDL
5. Increases synthesis of Apo AI and AII
![Page 56: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/56.jpg)
Fish Oil
• n-3 PUFA’s• Epidemiologic data on survival• GISSI-Prevenzione• Effects on Triglycerides
![Page 57: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/57.jpg)
Fish Oil
• 9 patients• 6 weeks
1 g/d N-3 PUFA1 U tocopherol/d
• 6 weeks5 g/d fish oil
• Slower VLDL and LDL oxidation
Hau et al. Arterio Thromb Vasc Biol 1996;16:1197
-54 -56
-40
23
-60
-50
-40
-30
-20
-10
0
10
20
30
TG VLDL TG VLDL-C LDL
![Page 58: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/58.jpg)
Fish Oil vs Gemfibrozil
29.7
11.0
-37.1
33.6
17.1
-40.4
-50
-40
-30
-20
-10
0
10
20
30
40
LDL HDL TG
FO Gemfib
Gemfibrozil 1,200 mg/dFish oil 4g/day
Stalenhoef et al Atherosclerosis 2000;153:129
![Page 59: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/59.jpg)
n-3 PUFA’s and SCD
Albert et al NEJM 2002;346:1113
![Page 60: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/60.jpg)
GISSI-Prevenzione
GISSI group, Lancet 1999;354:447
![Page 61: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/61.jpg)
Mediterranian Diet
J. THOMSON "Chart of the Mediterranean Sea" Edin.18I7
![Page 62: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/62.jpg)
Lyon Heart Trial
De Lorgeril et al Circulation 1999;99:779
•First MI•Randomized•Mediterranian vs Prudent•5 year trial stopped early
• <35% energy as fat• <10% energy saturated fat• <4% energy as linoleic acid• >0.6% of energy as alpha-linolenic (18:3 or n-3)
• Eat more bread• Eat more fish, less meat• Eat more vegetables• Must have fruit every day• All butter and margarine replaced with olive oil and canola oil
![Page 63: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/63.jpg)
Lyon Heart Trial
De Lorgeril et al Circulation 1999;99:779
Survival with:No MI
Survival with:No MIAnginaCHFCVAPEPeriph embol
Survival with:No MIAnginaCHFCVAPEPeriph embolStable anginaPTCA, CABGRestenosis
![Page 64: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/64.jpg)
Control(n=204)
Intervention(n=219)
LDL 4.23 mmol/L163.6 mg/dL
4.17 mmol/L161.3 mg/dL
Lyon Heart Trial
De Lorgeril et al Circulation 1999;99:779
Differences in LDL-C
![Page 65: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/65.jpg)
Plasmapheresis
•Apheresis = Pheresis = Hemapheresis
•Apheresis -- (Latin, Greek -- aphairesis)to take out, take away, snatch, detach,separation, or abstract.
![Page 66: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/66.jpg)
Combination Therapy
• Statin + niacin• Statin + fibrate• Statin + ezetimibe• Statin + resin
When in doubt, drop the statin to 20% of maximum dose,Add second drug
Titrate up while watching symptoms and LFT’s
![Page 67: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/67.jpg)
Combination Therapy
2. The dose of simvastatin should not exceed 10 mg daily in patients receiving concomitant medication with gemfibrozil. The combined use of simvastatin with gemfibrozil should be avoided, unless the benefits are likely to outweigh the increased risks of this drug combination.
Caution should be used when prescribing other lipid-lowering drugs (other fibrates or lipid-lowering doses (1 g/day) of niacin) with simvastatin, as these agents can cause myopathy when given alone. The benefit of further alterations in lipid levels by the combined use of simvastatin with fibrates or niacin should be carefully weighed against the potential risks of these combinations. Addition of fibrates or niacin to simvastatin typically provides little additional reduction in LDL-C, but further reductions of TG and further increases in HDL-C may be obtained.
Zocor Package Insert
![Page 68: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/68.jpg)
Combination Therapy
Crestor Package Insert
Fenofibrate: Coadministration of fenofibrate (67 mg three times daily) with rosuvastatin (10 mg) resulted in no significant changes in plasma concentrations of rosuvastatin or fenofibrate (see PRECAUTIONS, Drug Interactions, and WARNINGS, Myopathy/Rhabdomyolysis).
Gemfibrozil: Coadministration of gemfibrozil (600 mg twice daily for 7 days) with rosuvastatin (80 mg) resulted in a 90% and 120% increase for AUC and Cmax of rosuvastatin, respectively. This increase is considered to be clinically significant (see PRECAUTIONS, Drug Interactions, WARNINGS, Myopathy/Rhabdomyolysis, DOSAGE ANDADMINISTRATION).
![Page 69: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/69.jpg)
Special Considerations
![Page 70: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/70.jpg)
Central Obesity Contributes to Insulin Resistance
Abdominal fat:high rate of FA turnoverhigh rate of lipolysis
![Page 71: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/71.jpg)
Diabetes and Lipids
• Elevated LDL• Elevated TG’s• Low HDL
![Page 72: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/72.jpg)
LDL Sizing
• Ultracentrifugation• NMR• Gel elecrophoresis
![Page 73: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/73.jpg)
A
B
![Page 74: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/74.jpg)
Diabetes Atherosclerosis Intervention StudyDiabetes Atherosclerosis Intervention StudyDAISDAIS
Diabetes Atherosclerosis Intervention StudyDiabetes Atherosclerosis Intervention StudyDAISDAIS
1.1. DM II, DM II, with and without coronary interventionwith and without coronary intervention
2.2. Randomized, prospectiveRandomized, prospectivefenofibrate vs placebofenofibrate vs placebo
3.3. 418 randomized418 randomized4.4. Follow-up - 39.6 monthsFollow-up - 39.6 months5.5. End-pointsEnd-points
minimum lumen diameterminimum lumen diametermean segment diametermean segment diametermean % stenosismean % stenosis
![Page 75: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/75.jpg)
Diabetes Atherosclerosis Intervention StudyDiabetes Atherosclerosis Intervention StudyDAISDAIS
Diabetes Atherosclerosis Intervention StudyDiabetes Atherosclerosis Intervention StudyDAISDAIS
Variable All (n=405)
Fenofibrate (n=198)
Placebo (n=207)
LDL size + LDL 0.039* 0.073* 0.008 LDL size + apoB
0.041* 0.078* 0.008
LDL size + HDL 0.026** 0.041** 0.016 LDL size + TG 0.027** 0.056** 0.007 LDL size + LDL + apoB + HDL + TG
0.044** 0.082** 0.021
* = P < 0.001 ** = P < 0.05
Change in Percentage Diameter Stenosis
![Page 76: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/76.jpg)
Effect of Exercise on Lipids
Kokkinos Arch Int Med 1995:155:415
2906 menage 30-64 yearsexercise treadmill test to exhaustionclassified into 6 groups based on
average miles run per week
![Page 77: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/77.jpg)
Effect of Exercise on Lipids
Kokkinos Arch Int Med 1995:155:415
LDL, TG, HDL versus miles per week
40
45
50
55
60
0-2 mi 3-6 mi 7-10 mi 11-14 mi 15-20 mi 21-60 mi
Miles Run per Week
HD
L m
g%
0
20
40
60
80
100
120
140
LD
L m
g%
Y2
HDLLDLTG
![Page 78: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/78.jpg)
Trans-Fatty Acids
Lichtenstein NEJM 1999;340:1933
![Page 79: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/79.jpg)
Trans-Fatty Acids
Lichtenstein NEJM 1999;340:1933
![Page 80: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/80.jpg)
Summary
• Elevated TG’s are a risk factoratherosclerosispancreatitis
• Treat underlying cause• Use fibrates early• Use in combination carefully
![Page 81: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/81.jpg)
End
![Page 82: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/82.jpg)
Hypertriglyceridemia
• Familial chylomicronemiadeficiency or inhibitor of LPL or activator Apo C-IIeruptive xanthomas, abdominal paindiet Rx -- short-chain fatty acids
• Dysbetaliproproteinemiahomozygous for Apo E-2high IDL -- chylo and VLDL remnants accumulatediet therapy
• Familial endogenous hypertriglyceridemia• Familial combined hyperlipidemia
![Page 83: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/83.jpg)
Diet
![Page 84: Approach to the Management of Hypertriglyceridemia](https://reader036.fdocuments.in/reader036/viewer/2022062519/56815292550346895dc0b6e4/html5/thumbnails/84.jpg)
Digestion